Type-2 angiotensin II receptor · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Type-2 angiotensin II receptor shows clinical signal disease relevance led by diabetic neuropathy. 1 more disease program remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P50052. Start with diabetic neuropathy, then reuse UniProt P50052 as the stable protein anchor across project notes and exports.
Start with diabetic neuropathy, then reuse UniProt P50052 as the stable protein anchor across project notes and exports.
Type-2 angiotensin II receptor shows clinical signal disease relevance led by diabetic neuropathy. 1 more disease program remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with diabetic neuropathy because it currently carries clinical signal support. Linked drugs include OLODANRIGAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyType-2 angiotensin II receptor
Review this target as Type-2 angiotensin II receptor, mapped to UniProt P50052. Sequence length is 363 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Type-2 angiotensin II receptor as ChEMBL target CHEMBL4607, mapped to UniProt P50052. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Type-2 angiotensin II receptor is the right protein anchor across sources, using UniProt P50052 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why diabetic neuropathy is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Type-2 angiotensin II receptor |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P50052 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Type-2 angiotensin II receptor |
| UniProt Accession | P50052 |
| Component Type | Protein |
| Sequence Length | 363 aa |
Type-2 angiotensin II receptor
Review this target as Type-2 angiotensin II receptor, mapped to UniProt P50052. Sequence length is 363 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Type-2 angiotensin II receptor shows clinical signal disease relevance led by diabetic neuropathy. 1 more disease program remain visible in the same review block.
Start review with diabetic neuropathy because it currently carries clinical signal support. Linked drugs include OLODANRIGAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL385433 | 10.1 | IC50 | 0.08 | Preclinical |
| CHEMBL408403 | 10.1 | IC50 | 0.08 | Approved |
| CHEMBL1791308 | 10.1 | Ki | 0.08 | Preclinical |
| CHEMBL2392353 | 9.96 | Ki | 0.11 | Preclinical |
| CHEMBL338027 | 9.92 | IC50 | 0.12 | Preclinical |
| CHEMBL2391146 | 9.89 | IC50 | 0.13 | Clinical |
| CHEMBL404594 | 9.85 | Ki | 0.14 | Preclinical |
| CHEMBL938 | 9.82 | Ki | 0.15 | Approved |
| CHEMBL216061 | 9.74 | Ki | 0.18 | Preclinical |
| CHEMBL7550 | 9.7 | IC50 | 0.2 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 94 | 219 | 7.9 |
| cell-based format | 25 | 89 | 7.0 |
| cell membrane format | 12 | 160 | 8.0 |
| assay format | 10 | 297 | 7.0 |
| tissue-based format | 4 | 7 | 8.3 |
| organism-based format | 1 | 23 | 8.0 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| tissue-based format | 9 | 0 | — |
| assay format | 6 | 7 | 7.3 |
| cell-based format | 4 | 1 | 8.7 |